Actively Recruiting

Phase Not Applicable
Age: 21Years - 80Years
All Genders
NCT03394417

StrataXRT vs Standard Clinical Practice for the Prevention of Acute Dermatitis in Head and Neck Cancers Patients

Led by National University Hospital, Singapore · Updated on 2024-12-12

100

Participants Needed

1

Research Sites

446 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a phase IV, prospective, double-blind, randomized controlled trial with 2 study arms. The study population will be patients receiving chemoradiation for head and neck carcinomas, the majority of whom will be outpatients unless they require inpatient supportive care during treatment. There will be a 12 to 14-week longitudinal follow-up with 9 assessments conducted during this follow-up. The estimated duration of recruitment will be 6-8 years. Intervention group If a patient is allocated to the intervention group following randomization, the patient will be treated with StrataXRT. Control group If a patient is allocated to the control group following randomization, the patient will be treated with standard clinical practice which consists of aqueous cream.

CONDITIONS

Official Title

StrataXRT vs Standard Clinical Practice for the Prevention of Acute Dermatitis in Head and Neck Cancers Patients

Who Can Participate

Age: 21Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients who are 21 years of age or older
  • Histological diagnosis of head and neck carcinoma available
  • Patients who are to be treated with concurrent chemoradiation
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3
  • No known allergy to StrataXRT or silicone
  • Able to give written informed consent, or have written consent given on their behalf
Not Eligible

You will not qualify if you...

  • Patients who cannot apply the skin product or have it administered to them
  • Patients with comorbidities and/or on medications that may alter the response of the skin, such as connective tissue disorders
  • Patients with existing rashes or wounds in the radiation field at baseline
  • Patients receiving concurrent cetuximab during radiotherapy
  • Previous radiotherapy to the head and neck region
  • Female patients who are pregnant or breastfeeding
  • Unable to give written informed consent, or unable to have written consent given on their behalf

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

National University Hospital

Singapore, Singapore

Actively Recruiting

Loading map...

Research Team

D

David Chia

CONTACT

F

Fatin Aliyah Binte Hussin

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here